Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1619-7070 (Print) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE

Original Publication: Berlin : Springer-Verlag Berlin, 2002-

Brain/*metabolism ; N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology ; Serotonin Plasma Membrane Transport Proteins/*biosynthesis; Adolescent ; Adult ; Brain/drug effects ; Brain/pathology ; Female ; Follow-Up Studies ; Humans ; Isoquinolines/pharmacology ; Male ; Neurons/metabolism ; Positron-Emission Tomography/methods ; Serotonin Antagonists/pharmacology ; Serotonin Plasma Membrane Transport Proteins/metabolism ; Substance-Related Disorders/pathology

Purpose: Animal data suggest that the synthetic drug ecstasy may damage brain serotonin neurons. Previously we reported protracted reductions in the availability of the serotonin transporter (SERT), an index of integrity of the axon terminals of brain serotonergic neurons, in SERT-rich brain regions in current human ecstasy users. Comparison of current ecstasy users and former ecstasy users yielded some evidence that this reduction might be reversible. However, participant selection effects could not be ruled out. Therefore, follow-up examinations were performed in these subjects to test the following a priori hypothesis in a prospective longitudinal design that eliminates participant selection effects to a large extent: availability of the SERT increases towards normal levels when ecstasy use is stopped, and remains unchanged or is further decreased if use is continued.
Methods: Two follow-up positron emission tomography measurements using the SERT ligand [11C](+)McN5652 were completed by 15 current and nine former ecstasy users. All subjects used illicit drugs other than ecstasy, too. The time interval between repeated measurements was about 1 year. The time course of the availability of the SERT was analysed in the following SERT-rich regions: mesencephalon, putamen, caudate and thalamus.
Results: Current ecstasy users showed a consistent increase in the availability of the SERT in the mesencephalon during the study (Friedman test: p = 0.010), which most likely was caused by a decrease in the intensity of ecstasy consumption (Spearman correlation coefficient -0.725, p = 0.002). Former ecstasy users showed a consistent increase in SERT availability in the thalamus (Friedman test: p = 0.006).
Conclusion: Ecstasy-induced protracted alterations in the availability of the SERT might be reversible.

Comment in: Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):185-7. (PMID: 16283179)

Synapse. 1998 Jun;29(2):183-92. (PMID: 9593108)
J Pharmacol Exp Ther. 1999 Jul;290(1):136-45. (PMID: 10381769)
J Pharmacol Exp Ther. 1987 Apr;241(1):338-45. (PMID: 2883295)
Biol Psychiatry. 1988 Jul;24(3):299-309. (PMID: 2969755)
J Med Chem. 2000 Aug 10;43(16):3103-10. (PMID: 10956218)
Lancet. 1998 Oct 31;352(9138):1433-7. (PMID: 9807990)
J Neurosci. 2001 Dec 1;21(23):9414-8. (PMID: 11717374)
Psychopharmacology (Berl). 2001 Mar;154(3):251-60. (PMID: 11351932)
Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):427-30. (PMID: 12536247)
J Nucl Med. 2000 Sep;41(9):1465-77. (PMID: 10994724)
Psychopharmacology (Berl). 2003 Apr;167(1):85-96. (PMID: 12632248)
J Neurosci. 1999 Jun 15;19(12):5096-107. (PMID: 10366642)
Addiction. 2002 Dec;97(12):1531-6. (PMID: 12472637)
J Psychopharmacol. 2005 Jan;19(1):71-83. (PMID: 15671132)
Br J Psychiatry. 1999 Jul;175:63-9. (PMID: 10621770)
J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13. (PMID: 1522276)
Brain Res. 1998 Sep 14;805(1-2):241-54. (PMID: 9733975)
J Neurochem. 2004 Sep;90(5):1218-26. (PMID: 15312176)
J Nucl Med. 2003 Mar;44(3):375-84. (PMID: 12621003)
Nucl Med Commun. 2001 Aug;22(8):889-97. (PMID: 11473208)
Br J Pharmacol. 2001 Dec;134(7):1455-60. (PMID: 11724751)
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108. (PMID: 4202581)
J Cereb Blood Flow Metab. 2000 Feb;20(2):253-62. (PMID: 10698061)
Eur J Pharmacol. 1988 Apr 27;149(1-2):159-63. (PMID: 2899513)
J Neurosci. 1988 Aug;8(8):2788-803. (PMID: 2457659)
J Cereb Blood Flow Metab. 1999 Sep;19(9):967-81. (PMID: 10478648)
Arch Gen Psychiatry. 2001 Oct;58(10 ):901-6. (PMID: 11576026)
J Cereb Blood Flow Metab. 2003 May;23(5):612-20. (PMID: 12771577)
Pharmacol Biochem Behav. 2002 Apr;71(4):845-55. (PMID: 11888575)
Life Sci. 2002 Jul 5;71(7):751-7. (PMID: 12074934)
J Nucl Med. 1996 Mar;37(3):513-20. (PMID: 8772658)
Pharmacol Ther. 2003 Apr;98 (1):35-58. (PMID: 12667887)
Neurology. 2000 Jul 25;55(2):294-6. (PMID: 10908909)
J Pharmacol Exp Ther. 1996 Feb;276(2):846-54. (PMID: 8632358)
J Nucl Med. 2002 May;43(5):678-92. (PMID: 11994534)
J Nucl Med. 2006 May;47(5):815-26. (PMID: 16644752)
Forensic Sci Int. 1993 Dec;63(1-3):9-18. (PMID: 8138238)
Lancet. 2001 Dec 1;358(9296):1864-9. (PMID: 11741626)
Nucl Med Biol. 2005 Feb;32(2):123-8. (PMID: 15721757)
Am J Psychiatry. 2004 Jul;161(7):1181-9. (PMID: 15229049)

0 (Isoquinolines)
0 (Serotonin Antagonists)
0 (Serotonin Plasma Membrane Transport Proteins)
96GSK40TLP (McN 5652)
KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)

Date Created: 20050901 Date Completed: 20060622 Latest Revision: 20181113

20240829

10.1007/s00259-005-1850-8

16133393